Open an account

Hercules Capital

HTGC · NYSE

$16.28+$0.21 (+1.31%)TodayMarket closed ·
Prev close $16.07

About HTGC

Hercules Capital, Inc. is a business development company. The firm is focused on providing senior secured loans to venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The company is structured as an internally managed, non-diversified, closed-end investment company. Its business objectives are to increase its net income, net investment income, and net asset value, through its investments in primarily structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. The company invests in a range of companies active in the technology industry sub-sectors characterized by products or services that require advanced technologies, including computer software and hardware, networking systems, semiconductors, telecommunications equipment and media, semiconductor capital equipment, information technology infrastructure, and others.

Employees
100
Headquarters
San Mateo, California
Listed
Jun 9, 2005
Sector
Financials
Industry
Capital Markets
Website
htgc.com

HTGC key statistics

Market cap
3.05B
Price-earnings ratio
8.00
Dividend yield
15.79%
Average volume
1.14M
Volume
859.40K
Open price
$16.05
High today
$16.36
Low today
$16.01
52 Week high
$19.13
52 Week low
$13.70

Hercules Capital (HTGC) at a glance

As of Oct 20, 2026, Hercules Capital (HTGC) shares are priced at $16.28, giving the company a market cap of 3.05B, a price-to-earnings ratio of 8.00 and a dividend yield of 15.79%.

Today the stock has traded between $16.01 and $16.36. The current price is 1.7% above the day's low and 0.5% below its high.

Volume so far is 859.40K shares, below the average of 1.14M shares a day.

Over the past year Hercules Capital has ranged from $13.70 to $19.13, and now sits 48% of the way up that range.

Hercules Capital met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.50 per share against an estimate of $0.4934.

The average analyst price target is $19.89, 22.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 11 analystsAvg $19.89
Low
$17.17
Now
$16.28
High
$26.25

HTGC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 1.9% on average.

  1. Q3 FY24: reported $0.51 per share against an estimate of $0.5213
  2. Q4 FY24: reported $0.49 per share against an estimate of $0.5164
  3. Q1 FY25: reported $0.45 per share against an estimate of $0.4737
  4. Q2 FY25: reported $0.50 per share against an estimate of $0.4807
  5. Q3 FY25: reported $0.49 per share against an estimate of $0.4883
  6. Q4 FY25: reported $0.48 per share against an estimate of $0.5021
  7. Q1 FY26: reported $0.48 per share against an estimate of $0.4862
  8. Q2 FY26: reported $0.50 per share against an estimate of $0.4934

HTGC news

  • Press releaseBusiness Wire

    Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.

  • Press releaseBusiness Wire

    Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call

  • Press releaseBusiness Wire

    Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029

  • Avi Kapoor

    Wall Street's Most Accurate Analysts Give Their Take On 3 Financial Stocks With Over 10% Dividend Yields

  • Press releaseBusiness Wire

    Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

  • Press releaseBusiness Wire

    Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029

  • Press releaseBusiness Wire

    NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies

  • Press releaseBusiness Wire

    Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors

Similar companies

Companies in the same industry as Hercules Capital

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.